Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1103/physrevc.49.r1751 | DOI Listing |
Phytother Res
January 2025
Laboratory of Immunology and Inflammation, School of Life Sciences and Biopharmaceutics, Guangdong Pharmaceutical University, Guangzhou, China.
Renal fibrosis is the most common pathway for the development of end-stage renal disease (ESRD) in various kidney diseases. Currently, the treatment options for renal fibrosis are limited. Ferroptosis is iron-mediated lipid peroxidation, triggered mainly by iron deposition and ROS generation.
View Article and Find Full Text PDFJ Sci Food Agric
January 2025
Department of Food Technology, Fulda University of Applied Sciences, Fulda, Germany.
Background: Understanding the size and surface charge (ζ-potential) of particles in the mixed micellar fraction produced by in vitro digestion is crucial to understand their cellular absorption and transport. The inconsistent presentation of micellar size data, often limited to average particle diameter, makes comparison of studies difficult. The present study aimed to assess different size data representations (mean particle diameter, relative intensity- or volume-weighted size distribution) to better understand physiological mixed micelle characteristics and to provide recommendations for size reporting and sample handling.
View Article and Find Full Text PDFJ Diabetes Metab Disord
June 2025
Department of Physiology, Kampala International University, Western Campus, Ishaka, Uganda.
Purpose: Diabetes mellitus is a global health challenge that leads to severe complications, negatively impacting overall health, life expectancy, and quality of life. Herbal medicines, valued for their accessibility and therapeutic benefits with minimal side effects, have been promoted as potential treatments. Managing conditions like diabetes, characterized by free radical production and cytokine-driven inflammation, is vital due to the active components in plants that exert direct pharmacological effects.
View Article and Find Full Text PDFMol Ther Methods Clin Dev
December 2024
Research Institute, Children's Hospital of Orange County, Orange, CA, USA.
Mucopolysaccharidosis type I (MPS I) is a metabolic disorder characterized by a deficiency in α-l-iduronidase (IDUA), leading to impaired glycosaminoglycan degradation. Current approved treatments seek to restore IDUA levels via enzyme replacement therapy (ERT) and/or hematopoietic stem cell transplantation (HSCT). The effectiveness of these treatment strategies in preventing neurodegeneration is limited due to the inability of ERT to penetrate the blood-brain barrier (BBB) and HSCT's limited CNS reconstitution of IDUA levels.
View Article and Find Full Text PDFBackground: Bispecific T cell-engagers (BTEs) are engineered antibodies that redirect T cells to target antigen-expressing tumors. BTEs targeting various tumor-specific antigens, like interleukin 13 receptor alpha 2 (IL13RA2) and EGFRvIII, have been developed for glioblastoma (GBM). However, limited knowledge of BTE actions derived from studies conducted in immunocompromised animal models impedes progress in the field.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!